ViralClear Submits In Vitro Data on Merimepodib and Remdesivir Synergistic Activity Against the COVID-19 Novel Coronavirus to...
April 30 2020 - 9:20AM
BioSig Technologies, Inc. (Nasdaq: BSGM) today announced that an
article titled, “The IMPDH inhibitor merimepodib provided in
combination with the adenosine analogue remdesivir reduces
SARS-CoV-2 replication to undetectable levels in vitro”, was
submitted to an online peer-reviewed life sciences journal.
This manuscript is authored by Natalya Bukreyeva, Rachel A.
Sattler, Emily K. Mantlo, John T. Manning, Cheng Huang and Slobodan
Paessler of the UTMB Galveston National Laboratory and Dr. Jerome
Zeldis of ViralClear Pharmaceuticals, Inc. (“ViralClear”) as a
corresponding author.
This article highlights pre-clinical data generated under
contract with Galveston National Laboratory at The University of
Texas Medical Branch. The work was started with Trek
Therapeutics and after merimepodib was acquired by ViralClear
continued with ViralClear.
“The concentrations of merimepodib and remdesivir used in this
article are achievable by our oral merimepodib and intravenous
remdesivir.” said Dr. Zeldis, ViralClear’s Executive Chair and
co-founder. “We look forward to starting our first Phase II
clinical trial with merimepodid in COVID-19 patients upon receipt
of FDA permission.”
Merimepodib, a broad-spectrum anti-viral candidate, demonstrated
strong activity against COVID-19 in cell cultures in laboratory
testing. The molecule is currently undergoing extensive
pre-clinical antiviral testing. Upon receipt of FDA permission of
its IND, ViralClear intends to pursue development of this molecule
for the treatment of COVID-19 through clinical trials in Q2
2020.
Remdesivir is an adenosine analogue that displays broad-spectrum
antiviral activity against RNA viruses and has been developed by
Gilead Pharmaceuticals for the treatment of Ebola. Recent evidence
is mounting for this clinical activity of Remdesivir for treating
COVID-19 patients.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).The Company’s first product, PURE EP(tm)
System is a computerized system intended for acquiring, digitizing,
amplifying, filtering, measuring and calculating, displaying,
recording and storing of electrocardiographic and intracardiac
signals for patients undergoing electrophysiology (EP) procedures
in an EP laboratory.
About ViralClearBioSig’s subsidiary ViralClear
Pharmaceuticals, Inc., is seeking to develop a novel pharmaceutical
to treat COVID-19. Merimepodib is intended to be orally
administered, and has demonstrated broad-spectrum in vitro
antiviral activity, including strong activity against COVID-19 in
cell cultures. Merimepodib has been previously studied in 12
clinical trials, including 5 in patients with hepatitis C (1 Phase
1b, 1 Phase 2, 2 Phase 2a, and 1 Phase 2b), 1 in patients with
psoriasis (Phase 2), and six in healthy volunteers (Phase
I).
Forward-looking StatementsThis press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024